An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 05 May 2017
At a glance
- Drugs PRI 724 (Primary) ; Cytarabine; Dasatinib
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- Sponsors PRISM Pharma Co
- 02 May 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016.
- 19 Apr 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016.